Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Pharmacovigilance.Register Now
The Pharmacovigilance Roundtable Discussions Strategy Meeting is free to attend for qualified end-users. These include Senior Executives of Pharmacovigilance (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Pharmacovigilance, Risk Management, Drug Safety, Safety Surveillance, Clinical Safety, Patient Safety, Medical & Regulatory Affairs, Compliance, Post Authorisation Safety, Medical Safety, Epidemiology.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Senior Vice President Head of Global Drug Safety, Shire
Mariette joined the pharmaceutical industry from clinical practice in 1989, and had a progressive career in drug safety and held various leadership positions in drug safety and medical affairs at Organon (now Merck), Mayne Pharma (now Hospira), Forest Labs (now Allergan).
In 2014 she was recruited to establish and lead a new safety organization for Baxalta when Baxter split off its Bioscience division. With the Shire acquisition of Baxalta in 2016 she was appointed to lead the new safety organization for Shire.
Vice President Head of Drug Safety Therapeutics Area , Celgene
Vice President, Head of Safety, Ionis Pharmaceutical
Charles had been an invited speaker and a moderator on numerous safety topics (Safety assessments in pediatric drug development, Signal detection, risk management and safety communication strategies) and most recently as a keynote speaker on the impact of signal detection on benefit/risk assessment.
He has a medical degree with honors from Vinnitsa National Piragov Medical School in Ukraine, a Master’s degree in Public Health Epidemiology from Tulane University School of Public Health and Tropical Medicine.
Vice President, Head Global Patient Safety, Sanofi
He was a member of the Steering Committee of IMI PROTECT Project. He is also a member of the Scientific Advisory Committee of the IMEDS program, or Innovation in Medical Evidence Development and Surveillance, which is created under the Reagan-Udall Foundation to help advance the regulatory science needs of the FDA. Juhaeri is an Adjunct Faculty at the Gillings School of Global Public Health, University of North Carolina Chapel Hill, North Carolina. He received his Ph.D. in Epidemiology from the same university.
Vice President, Head of Global Pharmacovigilance Services, Takeda International Inc.
Vice President Global Patient Safety & Risk Management , Alnylam
Vice President, Pharmacovigilance, Amag Pharmaceuticals
With recognized leadership and educational skills along with real life pragmatic experience, he contributed to patient safety on national and international levels representing unique views. Dr. Simon appreciates and shares with his colleagues and audience, that patient safety is not only the task for medical and safety professionals. It is for all, at all times.
Global Safety Lead, Takeda
Fabio De Gregorio
Vice President, Head, Drug Safety Europe, EU QPPV
Prior to joining Shionogi in 2016, Fabio De Gregorio held various healthcare positions throughout Europe. Most recently, he worked with UBC (a pharmacovigilance service provider), in Geneva and London, and previously, as a QPPV and medical director with Tubilux Pharma S.p.A. in Rome, Italy. In addition to his 14 year experience in pharmacovigilance, he held positions as an associate ophthalmologist with Pannarale Ophthalmic Centre in Italy, and served as a post-graduate resident at different European ophthalmic centres, including Coimbra University (Portugal), Cantonal Hospital of Freiburg (Switzerland), and Barraquer Institute of Barcelona (Spain). Fabio De Gregorio is a GMC registered physician. He specialized in Ophthalmology and earned a PhD in patho-physiology of ocular microcirculation from the University “La Sapienza” of Rome.
Anders Lindholm, MD, PhD
VP, Therapeutic Area Head, Inflammation & Immunology, Drug Safety
Anders received his MD at the Karolinska Institute in Stockholm, from which he also earned a PhD in Clinical Pharmacology and Transplantation Surgery. He practiced as a transplantation surgeon in Sweden. His scientific production includes more than 80 publications in peer reviewed journals. Subsequent to the academic career, Anders spent six years at Novo Nordisk as a Clinical Leader leading successful filings for a rapid acting insulin analogue. For the last 15 years Anders has been TA Safety Head at J&J, Shire and Celgene providing oversight for a department of physicians and scientists developing safety evaluations, benefit-risk assessments, and RMPs.
The Westin Boston Waterfront
425 Summer St, Boston, MA 02210